Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study

Abroad (travel likely)RecruitingPHASE2

Conditions

Triple-negative Breast Cancer · Bone Metastases

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Contact: Study coordinator (Xiaolin Li) · 847678911@qq.com · +86-571-88122222

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Locally Advanced Triple Negative Breast Cancer · TNBC - Triple-Negative Breast Cancer

Abroad (travel likely)RecruitingEARLY_PHASE1

New York, United States

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Triple-negative Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Triple-negative Breast Cancer · TNBC - Triple-Negative Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Aarau, Switzerland · Basel, Switzerland

A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

Triple-Negative Breast Cancer (TNBC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China